In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche buys Igen, spins off new company

Executive Summary

In a $1.4bn deal that will settle years of ongoing litigation between the companies, Roche will acquire Igen for $47.25 a share (a 41% premium to current market average). It intends to later spin out a new company, Igen Integrated Healthcare LLC, which will be 100% owned by Igen's stockholders (they get one share of Igen Integrated to replace each Igen share) and provide it with $155mm in working capital.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies